Post-Conference Focus Morning - Friday, March 25
Continuous Processing in Applications in Cell & Gene Therapy, Vaccines & Non-Traditional Modalities
9:00 AM
The Future of mRNA Production: A Case Study in Continuous Manufacturing via QBD, PAT & Digital Twins
- A future looking methodology developed to implement Quality by Design (QbD) in continuous manufacturing for mRNA
- Potential pharmaceutical application and how this may impact development and manufacturing timelines & capacity
- Next steps to further scale this technology
Mark Geng
Principal Scientist
Moderna
Lei Zho
Sr. Research Associate, Process Development
Moderna
9:30 AM
FireSide Chat: Continuous Processing for Oligonucleotides & Exosomes
- Exosome manufacturing is a relatively new scientific field, with production is limited by sample purity and scalability, how are Exopharm overcoming these challenges through continuous processing?
- Can continuous processing be applied to allow the large-scale processing needed for commercialized products in oligonucleotides and Exosomes?
- What are the bottleneck to advancing continuous processing in these applications?
Mark Geng
Principal Scientist
Moderna
Martin Johnson
Senior Engineering Advisor, Process Design & Development
Eli Lilly and Company
Michael West
CTO
Exopharm
10:00 AM
Refreshment Break
10:30 AM Impinging Jet in Continuous Processing – A Bridge to Continuous Vaccine Production?
- Scale up of impinging jet in continuous processing to pilot scale
- Use of technology in vaccines
- Future work
David Voigtlaender
Director – Innovation Management
Evonik
11:10 AM
Panel Discussion: Continuous Processing Potential Outside of Traditional Small Molecule & Monoclonal Antibody Applications
- What technologies are available for cell, gene and vaccine continuous manufacturing?
- How close are these technologies to commercialization? - How easy are commercially available technologies able to be adapted to process needs?
- What are the drivers for exploring CM for modalities outside of the traditional small molecules & monoclonal antibodies?
Simon Hawdon
Principal Scientist
CPI Biologics
David Voigtlaender
Director – Innovation Management
Evonik
Michael McCaman
Managing Director
BPTG, BDO
12:00 PM
End of Focus Day